The global schizophrenia drug market size was valued at USD 6.8 billion in 2016 and is estimated to grow at a CAGR of 2.5% over the forecast period. Schizophrenia, a chronic disorder of the central nervous system, affects 1.0% of the global population or seven out of 1,000 individuals. The disorder characterized by symptoms such as hallucinations, thought disorders, inability to execute day-to-day functions is known to develop from a combination of genetic, chemical, and environmental factors.
Increase in number of patients seeking treatment and rising demand for improved healthcare infrastructure are expected to drive the market. The schizophrenia market remains replete with strong unmet needs. There is a need for innovation for the treatment of this debilitating disorder.
The report discusses about emerging markets in the Asia Pacific (APAC) region. China and India are emerging as an opportunity for market expansion. Factors such as beneficial healthcare reforms, large aging population, increased health awareness, and low-cost base are the major driving factors for market expansion in these two countries.
According to reports by the National Institute of Mental health (NIMH) and the World Health Organization (WHO), schizophrenia is known to impose substantial burden on patients, their families and society. In the U.S. alone, the disorder affects approximately 3.5 million people and about 4,000 new cases are reported every year.
Schizophrenia is diagnosed 1.4 times more frequently in males than females, as the onset is earlier in men. The peak age of onset is 20–28 years for males and 25–32 years for females.
The drugs prescribed for schizophrenia can be segmented by therapeutic class into first, second, and third-generation antipsychotics. Currently, second-generation and third-generation antipsychotics remain the standard of care in the schizophrenia treatment market.
The report highlights brands prescribed for the treatment of schizophrenia such as Abilify, Seroquel, Zyprexa, Latuda, Aristada, Saphris, Fanapt, Vraylar among others. Long-Acting Injectables (LAIs) are increasingly being developed as they offer several advantages such as decreased hospitalizations and improved treatment outcomes. The factors restraining the growth of the global schizophrenia drugs market would be stringent regulation around new product approvals and rising generic launches. Regulators demand direct assessment of benefits and risks using clinically-evident endpoints leading to higher cost of conducting clinical trials.
Currently, 20 products are undergoing clinical trials for the treatment of schizophrenia. Some of the drugs are expected to aim at new molecular targets for treating unmet needs associated with the disorder. Several market players are expected to work upon serving the unmet market needs, identifying new targets, and consequentially develop stronger drug pipelines.
The report highlights leading pipeline drugs to be launched in the forecast period. Results from clinical trials of these drugs reported positive top-line primary and secondary endpoint data. Apart from the typical serotonin and dopamine receptors, the drugs are expected to provide novel mechanisms for the treatment of schizophrenia.
Regionally, the global schizophrenia drug market was dominated by the U.S. with more than 50.0% share in 2016. The schizophrenia market is largely generic accounting for almost 65.0% of prescription volume.
Japan is estimated to witness the fastest growth over the forecast period due to developed healthcare system, rising awareness about early diagnosis, rising disposable income, and availability of effective treatment. The global schizophrenia drug market will collectively be driven by the growing awareness about mental disorders, increased expenditure on healthcare, and availability of effective treatment methods with demand for target specific and tailored treatments.
Some of the prominent players operating in this industry are Johnson & Johnson, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan, and Pfizer. Johnson & Johnson, Otsuka, and Lundbeck are focused on building the schizophrenia therapeutics market for Long-Acting Injectables and are expected to hold a significant position in the schizophrenia therapeutics market.
Patent expirations and rising clinical trial failures hurt several companies, most notably Eli Lilly, Pfizer, and AstraZeneca. The market share captured by generics is anticipated to grow in 2022 due to oral brands losing their patent exclusivity.
Base year for estimation
2017 - 2022
Revenue in USD Million & CAGR from 2016 to 2022
U.S., UK, Germany, Spain, Italy, France, Japan
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report provides an analysis of the industry trends in each sub-category as well as forecasts revenue growth 2016 to 2022. For this study, Grand View Research has segmented the schizophrenia therapeutics market based on therapeutic class and treatment:
Therapeutic Class Outlook (% Market Share; 2016 - 2022)
Aristada (Aripiprazole Lauroxil)
Treatment Outlook (% Market Share; 2016 - 2022)
Regional Outlook (% Market Share; 2016 - 2022)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.